Evidence map›Paper›PMID 38884994›Full record

ArticleJAMA network open2024

Epidemiologic Features of Recovery From SARS-CoV-2 Infection.

Elizabeth C Oelsner, Yifei Sun, Pallavi P Balte, Norrina B Allen, Howard Andrews, April Carson, Shelley A Cole, Josef Coresh, David Couper, Mary Cushman and 35 more

Erratum issuedAbstract read
In one paragraph

Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Observational
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Sex, hormones, and lung health.Physiological reviews · 2026
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Neuroimmune pathophysiology of long COVID.Psychiatry and clinical neurosciences · 2025
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

45 authors.

Elizabeth C OelsnerDivision of General Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, New York.
Yifei SunDepartment of Biostatistics, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York.
Pallavi P BalteDivision of General Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, New York.
Norrina B AllenCenter for Epidemiology and Population Health, Northwestern Feinberg School of Medicine, Chicago, Illinois.
Howard AndrewsDepartment of Biostatistics, Mailman School of Public Health, Columbia University Irving Medical Center, New York, New York.
April CarsonDepartment of Epidemiology, School of Public Health, University of Alabama at Birmingham.
Shelley A ColeTexas Biomed, San Antonio, Texas.
Josef CoreshDepartments of Medicine and Public Health, NYU Grossman School of Medicine, New York, New York.
David CouperCollaborative Studies Coordinating Center, Department of Biostatistics, University of North Carolina, Chapel Hill.
Mary CushmanDivision of Hematology/Oncology, Department of Medicine, Larner School of Medicine, University of Vermont, Burlington.
Martha DaviglusInstitute for Minority Health Research, University of Illinois College of Medicine, Chicago.
Ryan T DemmerDivision of Epidemiology, Department of Quantitative Health Sciences, College of Medicine and Science, Mayo Clinic, Rochester, Minnesota.
Mitchell S V ElkindDepartment of Neurology, Columbia University Irving Medical Center, New York, New York.
Linda C GalloDepartment of Psychology, San Diego State University, California.
Jose D GutierrezDepartment of Neurology, Columbia University Irving Medical Center, New York, New York.
Virginia J HowardDepartment of Epidemiology, School of Public Health, University of Alabama at Birmingham.
Carmen R IsasiDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.
Suzanne E JuddDepartment of Epidemiology, School of Public Health, University of Alabama at Birmingham.
Alka M KanayaDepartments of Medicine, Epidemiology, and Biostatistics, University of California, San Francisco.
Namratha R KandulaCenter for Epidemiology and Population Health, Northwestern Feinberg School of Medicine, Chicago, Illinois.
Robert C KaplanDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.
Gregory L KinneyDepartment of Epidemiology, University of Colorado Denver.
Anna M Kucharska-NewtonDepartment of Epidemiology and Environmental Health, University of Kentucky, Lexington.
Daniel T LacklandDepartment of Neurology, Medical University of South Carolina, Charleston.
Joyce S LeeDivision of Pulmonary and Critical Care, Department of Medicine, University of Colorado, Aurora.
Barry J MakeDivision of Pulmonary, Critical Care and Sleep, Department of Medicine, National Jewish Health, Denver, Colorado.
Yuan-I MinDepartment of Medicine, University of Mississippi Medical Center, Jackson.
Joanne M MurabitoDepartment of Medicine, Boston University, Boston, Massachusetts.
Arnita F NorwoodDepartment of Medicine, University of Mississippi Medical Center, Jackson.
Victor E OrtegaDivision of Pulmonary Medicine, Department of Medicine, Mayo Clinic, Phoenix, Arizona.
Kelley Pettee GabrielDepartment of Epidemiology, School of Public Health, University of Alabama at Birmingham.
Bruce M PsatyDepartments of Epidemiology and Medicine, University of Washington, Seattle.
Elizabeth A ReganDivision of Rheumatology, Department of Medicine, National Jewish Health, Denver, Colorado.
Daniela Sotres-AlvarezCollaborative Studies Coordinating Center, Department of Biostatistics, University of North Carolina, Chapel Hill.
David SchwartzDivision of Pulmonary and Critical Care, Department of Medicine, University of Colorado, Aurora.
James M ShikanyDivision of Preventive Medicine, Heersink School of Medicine, University of Alabama at Birmingham.
Bharat ThyagarajanDepartment of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis.
Russell P TracyDepartment of Pathology and Laboratory Medicine, University of Vermont, Burlington.
Jason G UmansMedStar Health Research Institute, School of Medicine, Georgetown University, Washington, District of Columbia.
Ramachandran S VasanSchool of Public Health, University of Texas School of Public Health San Antonio.
Sally E WenzelDepartment of Pulmonary, Allergy and Critical Care, Department of Medicine, University of Pittsburgh, Pennsylvania.
Prescott G WoodruffDivison of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of California, San Francisco.
Vanessa XanthakisSection of Preventive Medicine and Epidemiology, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.
Ying ZhangDepartments of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City.
Wendy S PostDivision of Cardiology, Departments of Medicine and Epidemiology, Johns Hopkins University, Baltimore, Maryland.

Funding

ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating CenterOT2HL156812 · NHLBI · RESEARCH TRIANGLE INSTITUTE · PI NOLEN, TRACY L, THOMAS, SONIA M · 2020 to 2024
$1270.7M
The Southwest National Primate Research Center Supplement- Infrastructure improvements of ABSL2 holding areasP51OD011133 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Larry S. Schlesinger · 2012 to 2026
$129.7M
UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
VCID and Stroke in a Bi-racial National CohortU01NS041588 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CUSHMAN, MARY, HOWARD, GEORGE · 2002 to 2022
$96.0M
ARIC Neurocognitive Study (ARIC-NCS) Renewal 2023-2028U01HL096812 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI JOSEF CORESH, THOMAS H MOSLEY · 2010 to 2026
$65.7M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Genetic Epidemiology of COPDU01HL089897 · NHLBI · NATIONAL JEWISH HEALTH · PI CRAPO, JAMES D · 2007 to 2021
$56.9M
Subclinical Vascular Contributions to Alzheimer's Disease: The Multi-Ethnic Study of Atherosclerosis (MESA) Multisite Study of AD (Renewal)R01AG058969 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Timothy M. Hughes, YONGMEI LIU · 2018 to 2026
$33.4M
Wake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3M
SPIROMICS II: Biological underpinnings of COPD heterogeneity and progressionU01HL137880 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WOODRUFF, PRESCOTT G · 2017 to 2021
$27.9M
Clinical and Translational Science AwardUL1TR000040 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$26.2M
Mechanisms of Familial Pulmonary FibrosisP01HL092870 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BLACKWELL, TIMOTHY S. · 2010 to 2020
$21.6M
Intramural NIH HHS Z01 ES101947NCATS NIH HHS UL1 TR000040NCATS NIH HHS UL1 TR001079NCATS NIH HHS UL1 TR001420NCI NIH HHS U01 CA260508NCRR NIH HHS UL1 RR024131NHLBI NIH HHS K23 HL130627NHLBI NIH HHS OT2 HL156812NHLBI NIH HHS P01 HL092870NHLBI NIH HHS R01 HL077612NHLBI NIH HHS R01 HL093009NHLBI NIH HHS R01 HL093081NHLBI NIH HHS R01 HL095393NHLBI NIH HHS R01 HL097163NHLBI NIH HHS R01 HL098433NHLBI NIH HHS R01 HL101250NHLBI NIH HHS R01 HL109282NHLBI NIH HHS R01 HL109284NHLBI NIH HHS R01 HL109301NHLBI NIH HHS R01 HL109315NHLBI NIH HHS R01 HL109319NHLBI NIH HHS R01 HL127028NHLBI NIH HHS R01 HL127659NHLBI NIH HHS R01 HL130506NHLBI NIH HHS R01 HL135009NHLBI NIH HHS R21 HL120770NHLBI NIH HHS R21 HL121457NHLBI NIH HHS R21 HL129924NHLBI NIH HHS R21 HL153700NHLBI NIH HHS R21 HL165405NHLBI NIH HHS U01 HL041642NHLBI NIH HHS U01 HL041652NHLBI NIH HHS U01 HL041654NHLBI NIH HHS U01 HL065520NHLBI NIH HHS U01 HL065521NHLBI NIH HHS U01 HL089856NHLBI NIH HHS U01 HL089897NHLBI NIH HHS U01 HL096812NHLBI NIH HHS U01 HL096814NHLBI NIH HHS U01 HL096899NHLBI NIH HHS U01 HL096902NHLBI NIH HHS U01 HL096917NHLBI NIH HHS U01 HL137880NHLBI NIH HHS U10 HL109086NHLBI NIH HHS U10 HL109146NHLBI NIH HHS U10 HL109152NHLBI NIH HHS U10 HL109164NHLBI NIH HHS U10 HL109168NHLBI NIH HHS U10 HL109172NHLBI NIH HHS U10 HL109250NHLBI NIH HHS U10 HL109257NHLBI NIH HHS U24 HL141762NHLBI NIH HHS UG3 HL151865NHLBI NIH HHS UH2 HL123442NIA NIH HHS R01 AG058969NIA NIH HHS R01 AG066162NIDDK NIH HHS P30 DK079626NIH HHS P51 OD011133NINDS NIH HHS R01 NS029993NINDS NIH HHS R01 NS048134NINDS NIH HHS R01 NS102715NINDS NIH HHS U01 NS041588
6 · The paper itself

Abstract

Importance: Persistent symptoms and disability following SARS-CoV-2 infection, known as post-COVID-19 condition or "long COVID," are frequently reported and pose a substantial personal and societal burden. Objective: To determine time to recovery following SARS-CoV-2 infection and identify factors associated with recovery by 90 days. Design, Setting, and Participants: For this prospective cohort study, standardized ascertainment of SARS-CoV-2 infection was conducted starting in April 1, 2020, across 14 ongoing National Institutes of Health-funded cohorts that have enrolled and followed participants since 1971. This report includes data collected through February 28, 2023, on adults aged 18 years or older with self-reported SARS-CoV-2 infection. Exposure: Preinfection health conditions and lifestyle factors assessed before and during the pandemic via prepandemic examinations and pandemic-era questionnaires. Main Outcomes and Measures: Probability of nonrecovery by 90 days and restricted mean recovery times were estimated using Kaplan-Meier curves, and Cox proportional hazards regression was performed to assess multivariable-adjusted associations with recovery by 90 days. Results: Of 4708 participants with self-reported SARS-CoV-2 infection (mean [SD] age, 61.3 [13.8] years; 2952 women [62.7%]), an estimated 22.5% (95% CI, 21.2%-23.7%) did not recover by 90 days post infection. Median (IQR) time to recovery was 20 (8-75) days. By 90 days post infection, there were significant differences in restricted mean recovery time according to sociodemographic, clinical, and lifestyle characteristics, particularly by acute infection severity (outpatient vs critical hospitalization, 32.9 days [95% CI, 31.9-33.9 days] vs 57.6 days [95% CI, 51.9-63.3 days]; log-rank P < .001). Recovery by 90 days post infection was associated with vaccination prior to infection (hazard ratio [HR], 1.30; 95% CI, 1.11-1.51) and infection during the sixth (Omicron variant) vs first wave (HR, 1.25; 95% CI, 1.06-1.49). These associations were mediated by reduced severity of acute infection (33.4% and 17.6%, respectively). Recovery was unfavorably associated with female sex (HR, 0.85; 95% CI, 0.79-0.92) and prepandemic clinical cardiovascular disease (HR, 0.84; 95% CI, 0.71-0.99). No significant multivariable-adjusted associations were observed for age, educational attainment, smoking history, obesity, diabetes, chronic kidney disease, asthma, chronic obstructive pulmonary disease, or elevated depressive symptoms. Results were similar for reinfections. Conclusions and Relevance: In this cohort study, more than 1 in 5 adults did not recover within 3 months of SARS-CoV-2 infection. Recovery within 3 months was less likely in women and those with preexisting cardiovascular disease and more likely in those with COVID-19 vaccination or infection during the Omicron variant wave.

Indexed as

COVID-19SARS-CoV-2AdultAgedFemaleHumansMaleMiddle AgedPandemicsPost-Acute COVID-19 SyndromeProspective StudiesUnited States

Identifiers

PMID38884994
PMCPMC11184459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.